Allogeneic stem cell transplantation in multiple myeloma
Abstract: The development of new inhibitory and immunological agents and combination therapies significantly improved response rates and survival of patients diagnosed with multiple myeloma (MM) in the last decade, but the disease is still considered to be incurable by current standards and the prognosis is dismal especially in high-risk groups and in relapsed and/or refractory patients. Allogeneic hematopoietic stem cell transplantation (allo-SCT) may enable long-term survival and even cure for individual patients via an immune-mediated graft-versus-myeloma (GvM) effect, but remains controversial due to relevant transplant-related risks, particularly immunosuppression and graft-versus-host disease, and a substantial non-relapse mortality. The decreased risk of disease progression may outweigh this treatment-related toxicity for young, fit patients in high-risk constellations with otherwise often poor long-term prognosis. Here, allo-SCT should be considered within clinical trials in first-line as part of a tandem approach to separate myeloablation achieved by high-dose chemotherapy with autologous SCT, and following allo-SCT with a reduced-intensity conditioning to minimize treatment-related organ toxicities but allow GvM effect. Our review aims to better define the role of allo-SCT in myeloma treatment particularly in the context of new immunomodulatory approaches
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Cancers. - 14 (2021) , 55, ISSN: 2072-6694
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2022
- Urheber
- DOI
-
10.3390/cancers14010055
- URN
-
urn:nbn:de:bsz:25-freidok-2236552
- Rechteinformation
-
Kein Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Greil, Christine
- Engelhardt, Monika
- Finke, Jürgen
- Wäsch, Ralph
- Universität
Entstanden
- 2022
Ähnliche Objekte (12)
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
The role of the APC/C and its coactivators Cdh1 and Cdc20 in cancer development and therapy
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Response to daratumumab-retreatment in patients with multiple myeloma
Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life
Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia
Correction to: Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia
Geriatric assessments and frailty scores in multiple myeloma patients : : a needed tool for individualized treatment?
Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab
Molekulare Mechanismen der Entstehung von B-Zell-Lymphomen des Menschen
Ein solid-phase-Radioimmunoassay zum Nachweis des Epstein-Barr-Virus-assoziierten Frühantigen-Komplexes (Early Antigen)
Prevention of bone disease and early detection of impending fractures in multiple myeloma patients can reduce morbidity and mortality: the necessity of interdisciplinary state-of-the-art treatment
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
The role of the APC/C and its coactivators Cdh1 and Cdc20 in cancer development and therapy
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Response to daratumumab-retreatment in patients with multiple myeloma
Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life
Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia
Correction to: Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia
Geriatric assessments and frailty scores in multiple myeloma patients : : a needed tool for individualized treatment?
Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab
Molekulare Mechanismen der Entstehung von B-Zell-Lymphomen des Menschen
Ein solid-phase-Radioimmunoassay zum Nachweis des Epstein-Barr-Virus-assoziierten Frühantigen-Komplexes (Early Antigen)
Prevention of bone disease and early detection of impending fractures in multiple myeloma patients can reduce morbidity and mortality: the necessity of interdisciplinary state-of-the-art treatment
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
The role of the APC/C and its coactivators Cdh1 and Cdc20 in cancer development and therapy
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Response to daratumumab-retreatment in patients with multiple myeloma
Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life
Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia
Correction to: Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia
Geriatric assessments and frailty scores in multiple myeloma patients : : a needed tool for individualized treatment?
Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab
Molekulare Mechanismen der Entstehung von B-Zell-Lymphomen des Menschen
Ein solid-phase-Radioimmunoassay zum Nachweis des Epstein-Barr-Virus-assoziierten Frühantigen-Komplexes (Early Antigen)